ID: ALA2381700

Max Phase: Preclinical

Molecular Formula: C31H35FN6O6S

Molecular Weight: 638.72

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  C#CCN(c1cnc(N(CC)CC)nc1N[C@@H](Cc1ccc(OC(=O)N2CCCC2)cc1)C(=O)O)S(=O)(=O)c1ccc(F)cc1

Standard InChI:  InChI=1S/C31H35FN6O6S/c1-4-17-38(45(42,43)25-15-11-23(32)12-16-25)27-21-33-30(36(5-2)6-3)35-28(27)34-26(29(39)40)20-22-9-13-24(14-10-22)44-31(41)37-18-7-8-19-37/h1,9-16,21,26H,5-8,17-20H2,2-3H3,(H,39,40)(H,33,34,35)/t26-/m0/s1

Standard InChI Key:  GRDNLKHOGQRLIU-SANMLTNESA-N

Associated Targets(Human)

Integrin alpha-5/beta-1 686 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Integrin alpha-V/beta-1 222 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Integrin alpha-L/beta-2 (LFA-1) 51 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Integrin alpha-4/beta-7 610 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Integrin alpha-4/beta-1 2269 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Cavia porcellus 23802 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Rattus norvegicus 775804 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mus musculus 284745 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Plasma 10718 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 638.72Molecular Weight (Monoisotopic): 638.2323AlogP: 3.99#Rotatable Bonds: 13
Polar Surface Area: 145.27Molecular Species: ACIDHBA: 9HBD: 2
#RO5 Violations: 1HBA (Lipinski): 12HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.09CX Basic pKa: 6.47CX LogP: 2.83CX LogD: 2.57
Aromatic Rings: 3Heavy Atoms: 45QED Weighted: 0.26Np Likeness Score: -1.40

References

1. Xu YZ, Konradi AW, Bard F, Dappen M, Dofiles L, Dreyer M, Gallager I, Garrido C, Krimm M, Liao Z, Messersmith E, Mutter L, Pleiss MA, Samant B, Semko CM, Smith J, Stappenbeck F, Stupi B, Vandervert C, Welch B, Wipke B, Yednock T..  (2013)  Arylsulfonamide pyrimidines as VLA-4 antagonists.,  23  (10): [PMID:23562062] [10.1016/j.bmcl.2013.03.010]
2. Xu YZ, Smith JL, Semko CM, Rossiter KI, Fukuda JY, Dappen MS, Quincy DA, Konradi AW, Mao W, Welch B, Dreyer ML, Samant B, Zhang H, Lugar J, Liao Z, Henschel C, Petersen E, Vandevert C, Shoemaker M, Wehner N, Mutter L, Shopp G, Krimm M, Chen L, Wipke B, Dofiles L, Gallager I, Sauer JM, Messersmith EK, Pleiss MA, Bard F, Yednock TA..  (2013)  Orally available and efficacious α4β1/α4β7 integrin inhibitors.,  23  (15): [PMID:23777782] [10.1016/j.bmcl.2013.05.076]

Source